Benchmark analyst Doug Becker initiates coverage on NOV (NYSE:NOV) with a Hold rating.
Sonnet BioTherapeutics Announces Updated Clinical Data For SON-1010 At The 2023 American Association For Cancer Research Annual Meeting
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010